摘要
目的探讨乙肝病毒感染弥漫大B细胞淋巴瘤患者通过利妥昔单抗联合化疗的疗效及安全性,为乙肝病毒感染弥漫大B细胞淋巴瘤患者的治疗提供新的思路和方案。方法回顾性分析2010年1月-2012年2月医院收治的乙肝病毒感染弥漫大B细胞淋巴瘤患者72例,按治疗方案不同分为观察组34例,采用利妥昔单抗联合化疗治疗,对照组38例患者则单用化疗治疗,分析两组患者的疗效结果、不良症状、患者肝功能损害程度、存活及HBV再激活情况。结果治疗后观察组患者有19例(55.88%)完全缓解,明显优于对照组6例(15.79%),且治疗总有效率差异有统计学意义(P<0.05);两组患者相关的不良反应发生率比较,差异无统计学意义;对两组患者的肝损害程度进行比较,发现观察组患者肝损害均为Ⅰ级,对照组中Ⅰ级损害1例、Ⅱ级损害3例、Ⅲ级损害1例,两组患者在各种程度的比较差异无统计学意义;通过对72例患者3年的随访记录发现,观察组患者在1、2、3年的存活率均明显高于对照组,差异有统计学意义(P<0.05);观察组中1例(2.94%)患者HBV再激活,对照组中无HBV再激活,两组差异有统计学意义(P<0.05)。结论利妥昔单抗联合化疗治疗对乙肝病毒感染弥漫大B细胞淋巴瘤患者有较好的疗效,在临床的应用上不会加重患者不良症状。
OBJECTIVE To investigate the efficacy and safety of rituximab plus chemotherapy for the treatment of the diffuse large B-cell lymphoma combined with hepatitis B virus,so as to provide new ideas and programs for treatment of patients with diffuse large B-cell lymphoma combined with hepatitis B virus.METHODS A total of 72 cases of patients with diffuse large B-cell lymphoma combined with hepatitis B virus from Jan.2010 to Feb.2012 in our hospital were retrospectively analyzed.According to the treatment methods,34 patients were selected as observation group using rituximab combined with chemotherapy,38 patients were selected as control group treated with chemotherapy alone,and the results of the efficacy of two groups of patients,the degree of adverse symptoms and liver dysfunction,survival and HBV reactivation of the two groups were analyzed.RESULTS After treatment for follow-up comparison,19patients（55.88%）in observation group after CR were significantly better than6patients（15.79%）in control group（P〈0.05）.There was no significant difference between the two groups on related adverse symptoms.Comparison of liver and the extent of liver damage in observation group and control group,all patients in observation group were gradeⅠ damage,and in control group,there were 1,3,and 1case of gradeⅠ,Ⅱ,and III damage,respectively.By 3years of follow-up records of 72 patients,it is found that 1,2,3-year deposit rates of observation group were significantly higher than those of control group（P〈0.05）.There was 1case（2.94%）of patient with HBV reactivation in observation group,and no case in control group.CONCLUSION Rituximab combined with chemotherapy for diffuse large B-cell lymphoma combined with hepatitis B virus has a good effect,and its clinical application does not aggravate adverse symptoms in patients.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2016年第19期4371-4373,共3页
Chinese Journal of Nosocomiology
基金
湖北省卫生厅科研基金资助项目(201303689)
关键词
乙肝病毒感染
弥漫大B细胞淋巴瘤
利妥昔单抗
化疗
Hepatitis B virus infection
Diffuse large B-cell lymphoma
Rituximab
Chemotherapy
